Investment Rating - The report maintains a "Buy" rating for the company, Lixun Precision, with a target price of RMB 52.8, indicating a potential upside of 17% from the current price of RMB 44.98 [1][5][22]. Core Insights - The company has shown steady growth in net profit, with a year-on-year increase of 23% in Q2 and an expected median growth of 22% in Q3. This growth is attributed to the synergy across various business segments, particularly in components and assembly for major clients, as well as significant revenue growth in the communications and automotive sectors [5][7]. - The report highlights that the automotive business, including the recently consolidated Lainie and ODM business, is expected to contribute positively to both revenue and profit in the coming years. Additionally, the company is poised for growth in AI servers and automotive smart cockpit technologies [5][9]. Financial Projections - Revenue projections for Lixun Precision are as follows: - 2023: RMB 231,905 million - 2024: RMB 268,795 million - 2025E: RMB 329,659 million (22.6% YoY growth) - 2026E: RMB 386,681 million (17.3% YoY growth) - 2027E: RMB 429,648 million (11.1% YoY growth) [2][6][9]. - Net profit projections are: - 2023: RMB 10,953 million - 2024: RMB 13,366 million - 2025E: RMB 16,673 million (25% YoY growth) - 2026E: RMB 20,937 million (26% YoY growth) - 2027E: RMB 25,418 million (21% YoY growth) [2][6][9]. Valuation - The report employs a sum-of-the-parts valuation method, assigning target price-to-earnings ratios for different business segments: - Consumer Electronics: 21x - Computers: 10x - Automotive: 35x - Communications: 34x - Industrial and Others: 20x - This results in a target price of RMB 52.8, reflecting a potential upside of 17% [5][10].

Investment Rating - The report maintains a "Buy" rating for the company, Xiaomi Group, with a target price of HKD 75.0, indicating a potential upside of 43% from the current price of HKD 52.55 [1][3][27]. Core Views - The short-term and long-term fundamentals of Xiaomi show growth potential, driven by strong demand in the new energy vehicle sector and ongoing investments in technology such as chips and AI [1][2]. - The company is expected to achieve a smartphone shipment of 175 million units in 2025, with high-end products supporting margin growth [1][3]. - The IoT segment is projected to grow nearly 50% due to the expansion of major appliances and overseas business [1][3]. - The internet business is anticipated to maintain stable revenue growth and high margins due to a growing user base [1][3]. - The automotive segment is expected to exceed the delivery target of 350,000 units, with scale effects and high-end models improving margins [1][3]. Financial Projections - Revenue is forecasted to grow from RMB 270.97 billion in 2023 to RMB 756.75 billion by 2027, with a compound annual growth rate (CAGR) of approximately 20% [3][12]. - Adjusted net profit is expected to increase significantly from RMB 19.27 billion in 2023 to RMB 71.50 billion in 2027, reflecting a CAGR of around 39% [3][12]. - The target price corresponds to a price-to-earnings (P/E) ratio of 29.9x, indicating room for valuation growth [2][13]. Segment Valuation - The report employs a sum-of-the-parts valuation method, assigning target P/E ratios of 23.0x for smartphones, 27.0x for IoT, and 20.0x for internet services, along with a target price-to-sales (P/S) ratio of 2.5x for electric vehicles [2][13]. - The total valuation for Xiaomi is estimated at HKD 75.0, based on projected revenues and net profits across its business segments [2][13].

Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to HKD 9.6, indicating a potential upside of 16% from the current price of HKD 8.31 [2][3]. Core Insights - The company's performance in the first half of 2025 (1H25) is stable, with a revenue of RMB 350 million, representing a 17% year-over-year increase. The gross margin is reported at 70.1%, a decrease of 2.6 percentage points year-over-year. The net loss attributable to shareholders is RMB 69.88 million, narrowing by 2% compared to the same period last year [2][3]. - The heart valve business is evolving from a focus on aortic stenosis (AS) to multiple indications including aortic regurgitation (AR) and transcatheter edge-to-edge repair (TEER). The company has three core valve products nearing commercialization, expected to be approved in 2026, which will contribute to revenue growth starting in 2027 [2][3][12]. - The neurointerventional segment has experienced a slowdown in revenue growth due to the impact of centralized procurement, but is expected to achieve over 20% year-over-year growth as procurement volumes stabilize [2][3]. Financial Performance Summary - For 1H25, the company reported revenues of RMB 350 million, with a gross profit margin of 70.1%. The net loss attributable to shareholders was RMB 69.88 million, showing improvement from the previous year [2][3]. - Revenue projections for the upcoming years are as follows: RMB 748 million in 2025, RMB 939 million in 2026, and RMB 924 million in 2027, with year-over-year growth rates of 21.5%, 25.6%, and -1.6% respectively [3][9]. - The company anticipates a gradual increase in revenue from its core products, with significant contributions expected from new product launches in 2027 [2][3][12]. Product Pipeline Overview - The company has a robust pipeline with several products in various stages of development. Key products include TaurusTrio (AR TAVR), TaurusNXT (third-generation AS TAVR), and GeminiOne (TEER), all expected to receive regulatory approval in 2026 [2][12]. - The company is also preparing for international market entries, with submissions for FDA and CE certifications for its products underway [2][12][13].

Investment Rating - The report maintains a "Buy" rating for Xiaopeng Motors (XPEV.US/9868.HK) [2][8] - The target price for Xiaopeng Motors (XPEV.US) is raised to $27.4, representing a potential upside of 15% [2][4] - The target price for Xiaopeng Motors-W (9868.HK) is raised to HKD 106.9, representing a potential upside of 16% [5][8] Core Insights - Xiaopeng Motors is entering a new product strength cycle, with models like MONA, P7+, G6, G9, and G7 driving sales growth and margin improvement [8] - The company expects to achieve breakeven in Q4 2025, supported by strong sales and improving gross margins [8] - The guidance for Q3 2025 indicates a median sales volume of 115,500 vehicles, a year-on-year increase of 148% and a quarter-on-quarter increase of 12% [8] Financial Forecasts - Revenue projections for Xiaopeng Motors from 2023 to 2027 are as follows: - 2023: RMB 30,676 million - 2024: RMB 40,866 million (33% YoY growth) - 2025E: RMB 76,780 million (88% YoY growth) - 2026E: RMB 105,987 million (38% YoY growth) - 2027E: RMB 141,072 million (33% YoY growth) [3][12] - Gross margin is expected to improve from 1.5% in 2023 to 17.9% in 2027 [3][12] - Net loss is projected to decrease from RMB 10,376 million in 2023 to a profit of RMB 4,206 million by 2027 [3][12] Valuation Methodology - The report employs a sum-of-the-parts valuation method, assigning a sales multiple of 2.2x for automotive sales and 5.0x for services and other revenues, leading to a target price of $27.4 for Xiaopeng Motors [8][16] - The target price for Xiaopeng Motors-W is derived similarly, resulting in HKD 106.9 [8][16] Recent Performance - In Q2 2025, Xiaopeng Motors reported revenue of RMB 18,274 million, a 125% increase year-on-year, with a gross profit of RMB 3,167 million [11] - The gross margin for Q2 2025 was 17.3%, up from 14.0% in Q2 2024 [11] - Vehicle sales volume reached 103,181 units in Q2 2025, a 242% increase year-on-year [11]

Investment Rating - The report maintains a "Buy" rating for the company and raises the target price for both the Hong Kong and A-share listings to HKD 27.0 and RMB 39.0 respectively [5][9]. Core Insights - The company reported a revenue of RMB 3.342 billion in Q2 2025, reflecting a year-on-year increase of 13.9% and a quarter-on-quarter increase of 7.9%, aligning closely with previous profit forecasts [1]. - The overall new order growth for the first half of 2025 continued at a rate of over 10% year-on-year, with the company maintaining its full-year revenue growth guidance of 10%-15% [4]. - The top 20 pharmaceutical companies showed strong revenue growth of 48% year-on-year in the first half of 2025, with expectations for continued growth in the second half [2]. Summary by Sections Financial Performance - In Q2 2025, the adjusted net profit attributable to the parent company was RMB 406 million, up 15.6% year-on-year and 16.3% quarter-on-quarter, slightly below expectations due to higher-than-expected losses from non-operating items [1]. - The gross margin for Q2 2025 was 33.7%, remaining stable year-on-year and quarter-on-quarter, while the adjusted net profit margin was 11.7%, showing a slight increase [1]. Revenue Breakdown - Laboratory services revenue grew by 15.2% year-on-year and 9.6% quarter-on-quarter, driven by strong growth in biological science services [3]. - CMC services revenue increased by 17.4% year-on-year and 0.5% quarter-on-quarter, primarily due to growth from top 20 pharmaceutical clients [3]. - Clinical research services revenue rose by 8.9% year-on-year and 10.0% quarter-on-quarter, although margins declined due to competitive pricing in the domestic market [3]. Market Outlook - The company expects continued revenue growth in the second half of 2025, although year-on-year growth may moderate due to a high base in the second half of 2024 [4]. - The report highlights that laboratory services and CMC will remain the main drivers of revenue growth, with profit margins expected to improve in the latter half of the year [4].

Trade Policy Insights - The uncertainty surrounding U.S. tariff policies has significantly decreased following agreements with major trading partners like Japan and the EU, with new tariff rates announced on July 31[5] - The new tariff framework categorizes countries into three groups, with tariffs ranging from 10% to over 50%, depending on trade agreements and trade balances with the U.S.[5] - The U.S. Department of Commerce is conducting up to 8 ongoing "Section 232 investigations," which could lead to additional tariffs on sectors like semiconductors and pharmaceuticals[6] Economic Data Overview - The U.S. core CPI inflation rate slightly increased in July, but the impact of tariffs on consumer prices is still emerging, with expectations that the influence will be less than previously anticipated[2] - Non-farm payroll data showed a weaker performance in July, with only 73,000 jobs added, significantly below the market expectation of 104,000[13] - The unemployment rate rose from 4.117% in June to 4.248% in July, indicating potential labor market weakness[13] Monetary Policy Outlook - The Federal Reserve is expected to restart interest rate cuts in September, with predictions of two additional 25 basis point cuts by the end of the year[3] - The potential for a 50 basis point rate cut is being considered, influenced by recent economic data trends[3] Currency and Market Predictions - The U.S. dollar index is projected to continue depreciating, with a year-end target of 95, reflecting concerns over economic momentum and labor market data[37] - The dollar index fell by 2.3% from the end of July to August 22, with significant declines against the euro, yen, and pound[36]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 525, representing a potential upside of 15% from the current price of HKD 456 [1][10]. Core Insights - The company's 1H25 performance exceeded expectations, with revenue of RMB 950 million and a narrowed net loss of RMB 145 million, which is a 146.8% year-over-year improvement [4]. - The sales of SKB264 reached RMB 302 million in the first half of the year, and the company maintains its first-year sales guidance of RMB 800-1,000 million [4]. - The company has successfully commercialized SKB264 in two indications and has a sales team of over 350 people, with sales established in over 1,000 hospitals across 29 provinces [4]. - The report highlights the upcoming ESMO conference where important data for SKB264 will be presented, which could further boost market confidence [4]. Financial Performance Summary - For 1H25, product revenue was RMB 310 million, with licensing revenue at RMB 630 million, slightly better than consensus estimates [4]. - The company’s cash and cash equivalents reached RMB 3.1 billion as of June 30, 2025, significantly up from RMB 1.34 billion at the end of 2024 [4]. - The report projects revenue growth with total revenue expected to reach RMB 2.286 billion in 2025, reflecting an 18.3% year-over-year increase [6]. Sales and Product Development - SKB264 has received preliminary approval for basic medical insurance and is expected to enter the insurance negotiations in the second half of the year [4]. - The company anticipates further approvals for additional indications of SKB264 in 2H25, which could enhance its market position [4]. - Other approved products, A167 and A140, are expected to contribute limited sales this year but may see significant growth once included in the insurance directory [4]. Valuation and Forecast - The report adjusts the 2025E net loss forecast to RMB 260 million and projects a net profit of RMB 220 million in 2026 [4]. - The target price of HKD 525 is derived from a DCF valuation model with a WACC of 8.7% and a perpetual growth rate of 3% [4].

Investment Rating - The report maintains a "Buy" rating for China Resources Beer (291.HK) with a target price of HKD 34.3, indicating a potential upside of 21.3% from the current price of HKD 28.3 [1][3]. Core Insights - China Resources Beer reported a 23% year-on-year increase in net profit attributable to shareholders for 1H25, reaching RMB 5.79 billion. The core operating profit, adjusted for one-time items, grew by 11.3% to RMB 7.1 billion, surpassing market expectations due to a significant reduction in unit costs and improved gross margins [1][5]. - The company is one of the few in the beer industry that achieved positive growth in average selling prices during a weak consumption environment, with a 0.4% increase in 1H25 [1][5]. - The new management's clear business development plans and positive outlook are expected to enhance market confidence in the company's future performance, potentially leading to better stock performance compared to peers [1][5]. Financial Performance Summary - **Sales Volume and Pricing**: In 1H25, beer sales volume increased by 2.2%, outperforming major competitors like Budweiser APAC, which saw an 8.2% decline. The average selling price rose by 0.4% due to a shift towards higher-end products, with premium and above products seeing over 10% growth [5][10]. - **Cost Management**: The unit cost decreased by 4.1% year-on-year, contributing to a 2.5 percentage point expansion in gross margin. The company's "Three Precision" strategy led to an 11% reduction in overall sales expenses [5][10]. - **White Spirit Business**: Despite a 34% drop in revenue from the white spirit segment due to regulatory challenges, the impact on overall performance is limited as this segment contributes a small portion to total revenue [5][10]. Financial Projections - **Revenue and Profit Forecasts**: The projected revenue for 2025 is RMB 39.13 billion, with a year-on-year growth of 1.3%. The net profit attributable to shareholders is expected to reach RMB 6.09 billion, reflecting a 28.5% increase [7][10]. - **Valuation Metrics**: The report provides a price-to-earnings (P/E) ratio forecast of 14.0 for 2025, with a return on equity (ROE) projected at 19.1% [7][10]. Market Positioning - The company is positioned to capture market share from competitors in the high-end segment, with significant growth opportunities in regions where its premium products are currently underrepresented [5][10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 146 / USD 38, indicating a potential upside of 21% from the current price [3][5][24]. Core Insights - The company's revenue for Q2 2025 reached RMB 356.7 billion, a year-on-year increase of 22.4%, surpassing market expectations by 6.5%. This growth was primarily driven by strong performance in the electronics category, benefiting from national trade-in policies [1][2]. - Service revenue grew by 29.1%, with advertising and logistics revenues increasing by 21.7% and 34.3%, respectively, largely due to the rapid growth of the food delivery business [1][2]. - Despite the strong revenue growth, adjusted net profit fell by 50% year-on-year to RMB 7.39 billion, attributed to a significant increase in marketing expenses, which rose by 128% to RMB 27 billion [2][3]. Summary by Sections Revenue Performance - Q2 2025 revenue was RMB 356.7 billion, up 22.4% year-on-year, with product revenue increasing by 20.7% and service revenue by 29.1% [1][2]. - The core category of electronics saw a 23.4% increase, driven by trade-in policies, while daily necessities grew by 16.4% [1]. Profitability Analysis - Gross margin for Q2 was 15.9%, a slight increase of 0.1 percentage points year-on-year. However, adjusted net profit dropped by 50% to RMB 7.39 billion, with an adjusted net profit margin of 2.1% compared to 5.0% in the previous year [2][3]. - The increase in sales expenses, particularly due to food delivery subsidies, led to a sales expense ratio increase from 4.1% to 7.6% [2]. Financial Forecasts - The report slightly raises the FY25E revenue forecast by 3.3%, projecting revenues of RMB 1,324.5 billion for FY25E [3][4]. - Adjusted net profit for FY25E is forecasted at RMB 25.63 billion, with a target P/E ratio of 15.5x [4][3].

Investment Rating - The report maintains a "Buy" rating for Leap Motor (9863.HK) and raises the target price to HKD 83.0, indicating a potential upside of 22% from the current price of HKD 68.15 [2][4]. Core Insights - Leap Motor's sales and net profit guidance for the year exceed expectations, with a target of 580,000 to 650,000 vehicles for 2025. The company anticipates significant growth in both domestic and overseas markets, supported by new model launches and partnerships [8]. - The gross margin is expected to improve, with a forecasted annual gross margin of 14%-15% for the year, driven by increased sales volume and better product mix [8]. - The valuation methodology used is a sum-of-the-parts approach, applying a price-to-sales ratio of 1.6x for 2025 sales, leading to the target price of HKD 83.0 [8]. Financial Performance and Forecast - For Q2 2025, Leap Motor reported revenue of RMB 14.23 billion, a year-on-year increase of 166% and a quarter-on-quarter increase of 42%. The gross margin was 13.6%, up 10.8 percentage points year-on-year [12]. - The company achieved a net profit of RMB 163 million in Q2 2025, marking a return to profitability after a loss in the previous quarter [12]. - Revenue projections for 2023 to 2027 show significant growth, with expected revenues of RMB 16.75 billion in 2023, increasing to RMB 108.44 billion by 2027, reflecting a compound annual growth rate [3][9]. Valuation and Market Position - The current market capitalization of Leap Motor is approximately HKD 91.11 billion, with an average trading volume of HKD 472.2 million over the past three months [4]. - The report highlights that Leap Motor's current price-to-sales ratio is 1.1x, suggesting potential for revaluation as the company continues to grow [8]. - The financial forecasts indicate a steady improvement in profitability, with net losses expected to turn into profits by 2025, projecting a net profit of RMB 634 million [3][9].